Leerink Partners Maintains Outperform on Zymeworks, Raises Price Target to $58
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Andrew Berens maintains Zymeworks (NASDAQ:ZYME) with a Outperform and raises the price target from $52 to $58.
Leerink Partners analyst Andrew Berens maintains Zymeworks (NASDAQ:ZYME) with a Outperform and raises the price target from $52 to $58.